Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Evaluation of the Clinical Usability of the SCD411 Prefilled Syringe as a Proposed Biosimilar to US-licensed Eylea®

NCT07501052 is registered in ClinicalTrials.gov with Sam Chun Dang Pharm. Co. Ltd. as lead sponsor.

NCT NCT07501052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07501052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Evaluation of the Clinical Usability of the SCD411 Prefilled Syringe as a Proposed Biosimilar to US-licensed Eylea®
Lead sponsor
Sam Chun Dang Pharm. Co. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
May 13, 2026
Completion date
June 1, 2026
Enrollment
33 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema, diabetic retinopathy, neovascular (wet) age-related macular degeneration, retinal vein occlusion